KR880004808A - 항신생 활성을 갖는 제약 조성물 - Google Patents

항신생 활성을 갖는 제약 조성물 Download PDF

Info

Publication number
KR880004808A
KR880004808A KR870011195A KR870011195A KR880004808A KR 880004808 A KR880004808 A KR 880004808A KR 870011195 A KR870011195 A KR 870011195A KR 870011195 A KR870011195 A KR 870011195A KR 880004808 A KR880004808 A KR 880004808A
Authority
KR
South Korea
Prior art keywords
agent
anticancer
anticancer agent
gsh
agent according
Prior art date
Application number
KR870011195A
Other languages
English (en)
Other versions
KR950013762B1 (en
Inventor
토그넬라 세르기오
테데쉬 미첼레
아쎄레또 로베르또
Original Assignee
마시밀리아노 판체라,세르기오 토그넬라
베링거 비오 케미아 로빈 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT21925/86A external-priority patent/IT1197485B/it
Priority claimed from IT8748339A external-priority patent/IT1211748B/it
Application filed by 마시밀리아노 판체라,세르기오 토그넬라, 베링거 비오 케미아 로빈 에스.피.에이 filed Critical 마시밀리아노 판체라,세르기오 토그넬라
Publication of KR880004808A publication Critical patent/KR880004808A/ko
Application granted granted Critical
Publication of KR950013762B1 publication Critical patent/KR950013762B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

항신생 활성을 갖는 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 글루타티온(GSH) 2.5-5g과, 백금 복합체, 옥사자포스포린, 안트라사이클린, 5-플루오로우라실 및 메토트렉세이트로 되는 군 중에서 선택된 1개 이상의 제암약제 유효량으로 되는, 제암 치료에 있어서 동시, 분리 또는 연속 사용을 위한 혼합 제제물 형태의 제암 상승 작용약제.
  2. 제1항에 있어서, 제암 약제가 시스-디클로로디아미노 백금, 시클로포스프아미드, 메토트렉세이트, 독소루비신(아드리아마이신)또는 5-플루오로우라실인 약제.
  3. 제1항 또는 제2항에 있어서, 제암 약제와 글루타티온이 분리된 단일 복용 형태인 약제.
  4. 제1항 또는 제2항에 있어서, 제암 약제와 글루타티온이 단위 복용 형태로 혼합된 약제.
  5. 상기 전 항 중 어느 하나의 항에 있어서, 제암 약제가 시스-디클로로디아민백금이고, GSH가 제암 약제 mg당 20내지 100mg의 양으로 존재하는 약제.
  6. 상기 전 항 중 어느 하나의 항에 있어서, 제암 약제가 시클로포스프아미드이고, GSH가 제암 약제 mg당 0.5내지 4mg의 양으로 존재하는 약제.
  7. 상기 전 항 중 어느 하나의 항에 있어서, 제암 약제가 독소루비신이고, GSH가 제암 약제 mg당 20내지 50mg의 양으로 존재하는 약제.
  8. 상기 전 항 중 어느 하나의 항에 있어서, 제암 약제가 메토트렉세이트이고, GSH가 제암 약제 mg당 0.3내지 15mg의 양으로 존재하는 약제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR87011195A 1986-10-07 1987-10-06 Pharmaceutical compositions having antineoplastic activity KR950013762B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT21925A/86 1986-10-07
IT21925/86A IT1197485B (it) 1986-10-07 1986-10-07 Composizioni farmaceutiche ad attivita' antineoplastica
IT8748339A IT1211748B (it) 1987-09-01 1987-09-01 Composizioni farmaceutiche ad atti vita'antineoplastica
IT48339A/87 1987-09-01

Publications (2)

Publication Number Publication Date
KR880004808A true KR880004808A (ko) 1988-06-27
KR950013762B1 KR950013762B1 (en) 1995-11-15

Family

ID=26328046

Family Applications (1)

Application Number Title Priority Date Filing Date
KR87011195A KR950013762B1 (en) 1986-10-07 1987-10-06 Pharmaceutical compositions having antineoplastic activity

Country Status (11)

Country Link
US (1) US4871528A (ko)
EP (1) EP0265719B1 (ko)
KR (1) KR950013762B1 (ko)
AU (1) AU605512B2 (ko)
CA (1) CA1306693C (ko)
DE (1) DE3768419D1 (ko)
ES (1) ES2036553T3 (ko)
GR (1) GR3001578T3 (ko)
HK (1) HK66594A (ko)
IL (1) IL84114A (ko)
PH (1) PH23232A (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3768419D1 (de) * 1986-10-07 1991-04-11 Boehringer Biochemia Srl Pharmazeutische zusammensetzungen mit antineoplastischer wirkung.
EP0334083B1 (de) * 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
WO1991002810A1 (en) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
IT1238078B (it) * 1990-01-31 1993-07-05 Silvano Spinelli Cis-platino complessi con ammine e sulfinilcarbossilati chelanti
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5618823A (en) * 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5378456A (en) * 1993-03-25 1995-01-03 American Cyanamid Company Antitumor mitoxantrone polymeric compositions
US5609867A (en) * 1994-11-01 1997-03-11 American Cyanamid Company Polymeric antitumor agents
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US20030203006A1 (en) * 1997-10-29 2003-10-30 Ajinomoto Co. Inc. Immunomodulator
US20070142267A1 (en) 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6312734B1 (en) 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
AUPQ641100A0 (en) * 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
GB0011059D0 (en) 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
GB0015447D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
GB0015446D0 (en) 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
GB0016447D0 (en) 2000-07-04 2000-08-23 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
IT1318696B1 (it) * 2000-09-15 2003-08-27 Pharmacia & Upjohn Spa Coniugati di glutatione con derivati della distamicina ad attivita'antitumorale.
GB0029004D0 (en) 2000-11-28 2001-01-10 Pharmacia & Upjohn Spa Process for preparing distamycin derivatives
US6969592B2 (en) 2001-09-26 2005-11-29 Pharmacia Italia S.P.A. Method for predicting the sensitivity to chemotherapy
ITMI20052449A1 (it) * 2005-12-22 2007-06-23 Cell Therapeutics Europe Srl Nuovi bis-platino complessi ad attivita' antitumorale
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3768419D1 (de) * 1986-10-07 1991-04-11 Boehringer Biochemia Srl Pharmazeutische zusammensetzungen mit antineoplastischer wirkung.

Also Published As

Publication number Publication date
GR3001578T3 (en) 1992-11-23
IL84114A (en) 1994-01-25
EP0265719A1 (en) 1988-05-04
CA1306693C (en) 1992-08-25
US4871528A (en) 1989-10-03
AU605512B2 (en) 1991-01-17
KR950013762B1 (en) 1995-11-15
DE3768419D1 (de) 1991-04-11
ES2036553T3 (es) 1993-06-01
HK66594A (en) 1994-07-15
PH23232A (en) 1989-06-06
AU7939887A (en) 1988-04-14
IL84114A0 (en) 1988-03-31
EP0265719B1 (en) 1991-03-06

Similar Documents

Publication Publication Date Title
KR880004808A (ko) 항신생 활성을 갖는 제약 조성물
KR900002784A (ko) 항종양치료에 사용하기 위한 약제학적 결합제제
DE69940674D1 (de) Orale verabreichung von adenosin analogen
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
NO308022B1 (no) Sammensetninger for orale preparater
GR3017282T3 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them.
RU94040855A (ru) Фармацевтическая композиция на основе эмульсии масло в воде для местного применения, содержащая ароматическое активное вещество
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
DE69521693T2 (de) Taxanderivate enthaltende arzneizubereitungen
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
Levi et al. A comparative clinical trial of 5‐azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia
ATE173627T1 (de) Medizinische zusammensetzung
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3'-디옥시티미딘-2'-엔(3'-디옥시-2',3'-디디하이드로티미딘)의 사용법
Cantin et al. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii
ES8207184A1 (es) Procedimiento para la preparacion de composiciones fosfoli- pidicas de colina
TR200200521T2 (tr) Parenteral cisplatin emülsiyonu.
KR890004705A (ko) 항바이러스성 제제
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
KR900013935A (ko) 대머리 환자의 발모촉진용 약제학적 조성물의 제조에 있어서 5'-데옥시-5'-메틸티오아데노신, s-아데노실메티오닌 및 이들 염의 용도 및 약제학적 조성물
ATE44467T1 (de) Fibrinolytisches mittel und diffusionsfaktor enthaltende pharmazeutische zusammensetzung verwendbar zur behandlung des myokardinfarktes.
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
KR870008885A (ko) 2-알콕시-n(1-아자비사이클로 [2,2,2] 옥트-3-일) 벤즈 아미드-n-옥사이드를 사용하여 구토증을 억제하는 방법
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
IL94621A0 (en) Pharmaceutical compositions containing vitamin a in association with various therapeutically active ingredients
FR2374036A1 (fr) Compositions pharmaceutiques contenant de la 3-phenoxypyridine

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20001108

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee